Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report)'s stock price gapped down prior to trading on Monday . The stock had previously closed at $86.70, but opened at $82.00. Axsome Therapeutics shares last traded at $79.42, with a volume of 1,141,458 shares changing hands.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on AXSM shares. StockNews.com raised Axsome Therapeutics from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. Robert W. Baird increased their price target on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 13th. Cantor Fitzgerald reissued an "overweight" rating and set a $121.00 price objective on shares of Axsome Therapeutics in a research note on Thursday, December 12th. Needham & Company LLC reiterated a "buy" rating and issued a $130.00 target price on shares of Axsome Therapeutics in a report on Monday. Finally, Royal Bank of Canada upped their price target on Axsome Therapeutics from $130.00 to $131.00 and gave the stock an "outperform" rating in a research note on Friday, October 4th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $125.93.
Read Our Latest Research Report on AXSM
Axsome Therapeutics Trading Down 2.2 %
The firm has a market cap of $4.11 billion, a P/E ratio of -12.98 and a beta of 1.18. The business's 50 day moving average is $93.26 and its 200-day moving average is $88.67. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.04. The company had revenue of $104.76 million during the quarter, compared to the consensus estimate of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same quarter in the previous year, the firm earned ($1.32) EPS. As a group, analysts forecast that Axsome Therapeutics, Inc. will post -4.6 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Axsome Therapeutics
Large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its holdings in shares of Axsome Therapeutics by 7.7% during the second quarter. Bank of New York Mellon Corp now owns 165,564 shares of the company's stock worth $13,328,000 after purchasing an additional 11,793 shares during the period. Rhumbline Advisers lifted its holdings in Axsome Therapeutics by 5.1% in the second quarter. Rhumbline Advisers now owns 54,931 shares of the company's stock worth $4,422,000 after acquiring an additional 2,674 shares during the last quarter. Arizona State Retirement System lifted its holdings in Axsome Therapeutics by 2.1% in the second quarter. Arizona State Retirement System now owns 8,630 shares of the company's stock worth $695,000 after acquiring an additional 177 shares during the last quarter. Torray Investment Partners LLC boosted its stake in Axsome Therapeutics by 11.5% in the second quarter. Torray Investment Partners LLC now owns 11,747 shares of the company's stock valued at $946,000 after acquiring an additional 1,209 shares during the period. Finally, WINTON GROUP Ltd grew its holdings in shares of Axsome Therapeutics by 156.6% during the second quarter. WINTON GROUP Ltd now owns 8,823 shares of the company's stock valued at $710,000 after purchasing an additional 5,385 shares during the last quarter. 81.49% of the stock is currently owned by institutional investors.
About Axsome Therapeutics
(
Get Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Further Reading
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
